@mpmbioimpact.bsky.social
We are a world-leading biotechnology investment firm with three decades of experience creating and investing in innovative companies seeking to deliver transformative therapies to patients. Find more info at https://mpmbioimpact.com/
ICYMI: Orna Therapeutics announced the appointment of Joseph Bolen, Ph.D., as CEO! Dr. Bolen, an MPM BioImpact Entrepreneur Partner, most recently served as Orna’s Chief Scientific Officer and is the ideal leader to advance its potentially best-in-class panCAR programs into the clinic next year.
Earlier this morning, DBV Technologies announced a PIPE, of up to $306.9M led by MPM BioImpact! DBV is committed to a critical mission, developing novel treatments that can potentially transform the care of food-allergic patients.
Congrats to Cullinan Therapeutics, which announced that its Phase 2b trial in patients with NSCLC met its primary endpoint! Cullinan was founded by MPM BioImpact and is committed to treating a variety of cancer and autoimmune disorders with high unmet medical needs. Learn more: bit.ly/3Cu39V0
Congrats to the recipients of the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant: Drs. Nika N. Danial and Karin Pelka! We are proud to support paradigm-shifting research, which may advance our understanding of cancer and transform future clinical practice.
We are happy to join BlueSky! Keep a look out for exciting news on our portfolio companies and our firm, as well as our insights about the biotech industry!